USDA Approves New Combination Vaccine To Fight BRD Viruses And Bacteria

USDA has approved Titanium 5 + PH-M, a new Elanco vaccine that protects cattle against the viruses and bacteria most associated with Bovine Respiratory Disease ( BRD).

 

 

Click on the photo above to download a high-resolution file suitable for printing.

USDA has approved Titanium 5 + PH-M, a new vaccine that protects cattle against the viruses and bacteria most associated with BRD.

 

The U.S. Department of Agriculture (USDA) has issued a Veterinary Biologics License for Titanium® 5 + PH-M, a new vaccine that protects cattle against the viruses and bacteria most associated with bovine respiratory disease (BRD).

Marketed by Elanco, Titanium 5 + PH-M provides modified-live virus (MLV) protection against bovine viral diarrhea (BVD), types 1 and 2, bovine respiratory syncytial virus (BRSV), infectious bovine rhinotracheitis (IBR) and parainfluenza3 (PI3).1-9 Each dose also protects against Mannheimia haemolytica10 and Pasteurella multocida bacteria, and is safe for cattle at all stages of production.3,5-7,11-16

“This means veterinarians and producers can protect cattle against the important BRD-causing viruses and bacteria with just one vaccine,” says Brett Terhaar, D.V.M., Elanco beef technical services. “Titanium 5 + PH-M is well-suited for branding and weaning/preconditioning vaccination protocols in cow/calf operations, as well as arrival programs in stocker operations and feedyards. Producers should partner with their veterinarians to determine the best way to incorporate this new vaccine into herd-health protocols designed to fight BRD.”

Viruses and bacteria: a powerful one-two punch on the immune system

Respiratory viruses can cause BRD on their own, but they also can compromise the immune system that normally protects cattle against bacteria. This allows bacteria to attack their host and cause severe cases of BRD.

“When cattle are exposed to respiratory viruses, their immune system can be weakened,” says Terhaar. “Once that happens, M. haemolytica and P. multocida bacteria can more easily go deep into the respiratory tract. When they reach the lungs, bacterial pathogens are a major cause of serious BRD, leading to increased illness and death.”

BRD still is the No. 1 profit-robber, accounting for 75 percent of feedlot morbidity, and 50 percent to 75 percent of mortality, costing an estimated $800 million to $900 million annually.17-20 Beyond that, one study showed 68 percent of untreated calves had pulmonary lesions at slaughter — demonstrating that a significant number of animals never diagnosed with BRD do, in fact, suffer from some form of respiratory disease.21

A combination vaccine for convenience, effectiveness and safety

Titanium 5 + PH-M is a combination of two trusted vaccines. Its viral component, Titanium 5, delivers modified-live protection against five important viruses that cause BRD. Its PH-M component provides coverage against two bacteria that are well-known for causing pasteurellosis (part of the BRD complex).

The new vaccine is formulated with a low-reactive, water-soluble adjuvant. The result is a low-volume (2 mL), subcutaneous dose that is consistent with Beef Quality AssuranceSM (BQA) guidelines.

Approved for use in cattle 60 days of age and older, Titanium 5 + PH-M is backed by noninterference, efficacy and safety research. It can be given to pregnant cows and heifers,* as well as calves nursing pregnant cows.**

“This means added flexibility as veterinarians and producers develop vaccine protocols to protect cattle at all stages of production against BRD,” says Terhaar. “Adding Titanium 5 + PH-M to the portfolio of ViralignTM 6, Master Guard® and other Titanium brand vaccines gives a variety of choices for delivering protection against challenging diseases.”

Titanium 5 + PH-M is available in convenient 10-dose and 50-dose packages through veterinarians and animal-health distributors. For more information, see the product label, contact your Elanco sales representative or technical consultant, or visit Elanco.us.

About Elanco
Elanco is a global innovation-driven company that develops and markets products to improve animal health and food animal production in more than 75 countries. Elanco employs more than 3,500 people worldwide, with offices in more than 40 countries, and is a division of Eli Lilly and Company, a leading global pharmaceutical corporation. Additional information about Elanco is available at www.elanco.com.

###

 

The label contains complete use information, including cautions and warnings. Always read, understand and follow the label and use directions. Do not vaccinate within 21 days of slaughter.

Elanco, Master Guard®, Titanium®, Viralign and the diagonal bar are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

*Titanium 5 + PH-M may be administered to pregnant cattle provided they were vaccinated, according to label directions, with Titanium 3, Titanium 4 L5, Titanium 5, Titanium 5 L5 HB or Titanium 5 + PH-M 30 to 60 days prior to breeding.
**Titanium 5 + PH-M may also be administered to calves nursing pregnant cows provided their dams were vaccinated as described above.

1Efficacy study for BRSV fraction to demonstrate compatibility of the BRSV component in APHIS product code: 45B9.20 (unlicensed). Study No. 2011-05 Rev. 1.
2Terhaar, B. Interleukin-2 receptor response to Titanium 5 L5. Study No. TR-08. Published by Agri Laboratories Ltd.
3Demonstration of the compatibility of components between APHIS product codes 1181.20 (Establishment 213) and G935.04 (Establishment 315) APHIS product code 45B9.20. Study No. 2010-01 Rev. 1.
4Titanium and Master Guard vaccines: Flexibility for preconditioning. Published by Agri Laboratories Ltd.
5Terhaar, B. 1999. A comparison of Titanium 5 L5 and Bovishield 4 L5 following virulent infectious bovine rhinotracheitis virus challenge. Study No. TR-04. Published by Agri Laboratories Ltd.
6Post-vaccinal body temperature response in cattle. Agri Laboratories Ltd.
7Ohnesorge, W. C. 1998. Immunogenicity of a modified live bovine viral diarrhea virus, type 1 and type 2, vaccine following BVDV 890 (type 2) challenge. Study No. 97-24.
8Immune response of calves to MLV and killed vaccines at branding and weaning — in the face of maternal antibodies. Study No. TR-20. Published by Agri Laboratories Ltd.
9Endsley, J. J., M. J. Quade, B. Terhaar, and J. A. Roth. 2002. Bovine viral diarrhea virus type 1- and type 2-specific bovine T lymphocyte-subset responses following modified-live virus vaccination. Vet. Ther. 3(4):364-372.
10Milliken, G. A. 2013. Mannheimia haemolytica efficacy studies demonstrating the absence of excessive interference of Titanium products with the Mannheimia haemolytica-Pasteurella multocida bacterin-toxoid.
11Porter, M. 2011. Field safety evaluation of bovine rhinotracheitis-virus diarrhea-parainfluenza3-respiratory syncytial virus vaccine, modified live virus, APHIS product code 1181.20 (establishment 213) in combination with Mannheimia haemolytica-Pasteurella multocida bacterin-toxoid, APHIS product code: G935.04 (establishment 315). Protocol No. 2011-01, Rev. 02.
12Field safety evaluation in pregnant cows. Study No. 02-11 Rev. No. 1. Published by Agri Laboratories Ltd.
13Terhaar, B. 2001. Evaluating the effects of vaccine-induced stress on productivity. Study No. TR-13. Published by Agri Laboratories Ltd.
14Terhaar, B. Effect of vaccination with Titanium 5. Study No. TR-11. Published by Agri Laboratories Ltd.
15Terhaar, B. 2000. Effect of vaccination with Titanium 5 on milk production in dairy cattle. Study No. TR-09. Published by Agri Laboratories Ltd.
16Terhaar, B. 1998. Final report on field safety evaluation of Titanium 5 L5. Study No. TR-03. Published by Agri Laboratories Ltd.
17Edwards, A. J. 1996. Respiratory Diseases of Feedlot Cattle in the Central USA. Bovine Practitioner. 30:5-7.
18Galyean, M. L., L. J. Perino and G. C. Duff. 1999. Interaction of Cattle Health/Immunity and Nutrition. J. Anim. Sci. 77:1120-1134.
19Loneragan, G. H., D. A. Dargatz, P. S. Morley, and M. A. Smith. 2001. Trends in Mortality Ratios Among Cattle in US Feedlots. J. Am. Vet. Med. Assoc. 219:1122-1127.
20Chirase, N. K. and L. W. Greene. 2001. Dietary zinc and manganese sources administered from the fetal stage onwards affect immune response of transit stressed and virus infected offspring steer calves. Animal Feed Science and Technology. 93:217-228.
21Wittum T. E., N. E. Woollen, L. J. Perino and E. T. Littledike. 1996. Relationships among treatment for respiratory tract disease, pulmonary lesions evident at slaughter, and rate of weight gain in feedlot cattle. J. Am. Vet. Med. Assoc. Aug 15;209(4):814-8.
 

Sponsored Introduction Continue on to (or wait seconds) ×